| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 658.7 | 597.8 |
| Net income | 218.1 | 193.6 |
| EPS (diluted, $ a share) | $0.85 | $0.69 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +12.7% |
|---|---|
| Revenue, year on year | +10.2% |
| Operating margin | 40.8% |
10-Q filed with the SEC, NASDAQ: EXEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Exelixis, Inc.: key numbers
- Share price
- $67.10Close, Nov 16
- Market cap
- $16.4B
- Shares outstanding
- 244.01MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Exelixis, Inc.
All →Exelixis Financial Results
Exelixis reported third quarter 2026 total revenues of $658.7 million, driven by $604.9 million in net product revenues from the cabozantinib franchise. The company achieved GAAP net income of $218.1 million and is focused on advancing its zanzalintinib development program and clinical pipeline.
- Term
- Q3 2026
“Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity. The zanzalintinib development program gained further momentum as the organization focused on trial initiations, enrollment progress for ongoing studies and in-depth planning for the next wave of new pivotal trials.”
Michael M. Morrissey, Ph.D., President and Chief Executive Officer